... EN ESTADOS UNIDOS SU APROBACIÓN SE PRODUCIRÁ EN BREVE . LA EMA EN ESTA OCASIÓN SE HA ADELANTÓ A LA USFDA EN LA APROBACIÓN DE UN TRATAMIENTO .
*.- CARBOPLATINO + ETOPÓSIDO .
*.- CISPLATIN + ETOPÓSIDO .
*.- ATEZOLIZUMAB .
*.- DURVALUMAB .
- SERPLULIMAB is the world's first anti-PD-1 Monoclonal Antibody (mAb) Approved for FIRST-LINE Treatment of ES-SCLC .
- SERPLULIMAB is the FIRST and only anti-PD-1 mAb Approved in the European Union (EU) for the Treatment of ES-SCLC .
- SERPLULIMAB Has Now Been Approved in China, Europe, and several Southeast Asian Countries, Benefiting Over 90,000 Patients .
This APPROVAL establishes SERPLULIMAB as the FIRST and Only anti-PD-1 mAb Approved in the EU for the Treatment of ES-SCLC.
SERPLULIMAB is the world's FIRST Anti-PD-1 mAb Approved For FIRST-LINE Treatment of ES-SCLC. Underpinned by Clinical Needs, Henlius has carried out a differentiated and multi-dimensional layout of SERPLULIMAB in the fields of Lung Cáncer and Gastrointestinal Cáncer . To date, more than 4,800 subjects have been enrolled Worldwide for clinical trials of SERPLULIMAB . In 2023, Henlius entered into a collaboration with INTAS Pharmaceuticals, granting INTAS Exclusive Rights to Develop and Commercialise SERPLULIMAB in Over 50 Countries Across Europe and India .
This Latest APPROVAL covers all 27 EU Member States as well as the European Economic Area Countries, including Norway, Iceland, and Liechtenstein. Commercialisation in Europe will be led by INTAS' Subsidiary, Accord Healthcare Ltd ("Accord") .
...
.jpeg)
.jpg)
.jpeg)
.jpeg)
%20(4)%20(1).jpeg)
%20(7).jpeg)
.jpeg)
.jpeg)
.jpeg)
.jpeg)
